Seattle, November 2, 2010 / PRNewswire-FirstCall / - Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the tax credits under the treatment program, which received $ 977,917 , as the U.S. government has awarded a grant of "Protecting the patient and the right to affordable health care. The program targets projects that could respond to new opportunities for therapies unmet medical needs, reduce health care costs against the long-term effects of cancer treatment to be demonstrated. City Telecom, Telecom City pixantrone Fellowship Program honor Brostallicin Opaxio and are subject bisplatinates in oncology.
"We are very pleased that the U.S. Department of Health and Social Services, the potential impact of the ITC's research and drugs can be detected in patients cured particular efforts to promote cancer," said James A. Bianco, MD, CEO of cell therapy. "The program is also on the contribution of the biotechnology industry is the importance of U.S. health care system. These grants allow CTI to continue to promote efforts in areas of unmet medical needs of the candidate's address of the product. "
About Cell Therapeutics, Inc.
Based in Seattle, CTI is a biopharmaceutical company that develops the treatment of cancer, it aims at providing an integrated portfolio of oncology products. For more information, please visit www.CellTherapeutics.com.
Sign in to receive e-mail alerts and RSS feeds available on our website
This press release contains forward-looking statements that involve risks and uncertainties that could materially affect the results and / or future results and the price of CTI stock market. In particular, the risks and the preclinical and clinical development of biopharmaceutical industry in the context of general insecurity and the ability of CTI to continually improve the efficiency of capital required, competitive factors, technological development, costs development, production and sale of the product candidate may not guarantee City Telecom's product candidate for a new therapeutic approach to meet the medical costs of health care to lower long-term growth or progress in healing cancer have risk factors listed or described from time to time that the ITC, but not limited to requests of the Securities and Exchange Commission, such as SIC applicant's limited over the last 10 - Form K, Form 10 - Q and Form 8 - K. You can also do so under the law, CTI does not intend to update or change is the result of new information, events or other materials.
Source of cell therapy companies
Source: PR Newswire
More news from this category
No comments:
Post a Comment